Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | WU-NK-101 |
Synonyms | |
Therapy Description |
WU-NK-101 are cytokine-reprogrammed natural-killer (NK) cells, which potentially induce cytotoxicity in tumor cells and antitumor activity (J Clin Oncol 41, no. 4_suppl (February 01, 2023) 170). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
WU-NK-101 | WU-NK 101|WU-NK101 | WU-NK-101 are cytokine-reprogrammed natural-killer (NK) cells, which potentially induce cytotoxicity in tumor cells and antitumor activity (J Clin Oncol 41, no. 4_suppl (February 01, 2023) 170). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05470140 | Phase I | WU-NK-101 | A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) | Active, not recruiting | USA | AUS | 0 |